Inclusion Criteria:

• Female
• Age 45 (inclusive) to 55 years (inclusive)
• Race: Caucasian
• Non-smokers / Smokers up to 10 cigarettes/day
• Postmenopausal hormone status: 1-3 years since the last spontaneous menstrual bleeding and a follicle-stimulating hormone concentration (FSH) >75 IU/ml and 17-estradiol (E2) of < 20 ng/L
• Years since menopause between 1-3 years
• Natural menopause or total hysterectomy with bilateral salpingo-oophorectomy
• Subjects with E2 results within the inclusion criteria range will be assessed on an individual basis if FSH level is less than 75 IU/ml
• Assessed as age-related healthy, based on a pre-study examination including medical history, physical examination, ECG, vital signs and clinical laboratory. The examination will be performed by a MD at the study site within 1-2 months prior planned study start for the individual subject.
• Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements.
• Ability to understand, speak, read and write the English language

Exclusion Criteria:

• T-score < -2.5 at total hip and spine (either or both)
• Suspect lack of compliance
• BMI > 30 or < 21
• Use of HRT within the previous 6 months
• Use of any drug which might interfere with bone-metabolism (bisphosphate, estrogen receptor modulators, calcitonin) within the previous 12 months
• Systematic practice of high intensity exercise
• Vegetarian nutrition or any other extreme dietary habits
• Use of dietary supplements while on study, except multi vitamin. No "wash out" period for supplements - must stop before run-in period and refrain until the end of the study.
• Participant in any other study or donation of blood during the last 30 days before start of each dosing phase (T0).
• Total genistein blood concentrations of > 100 ng/ml measured at pre-study examination
• Known hypersensitivity or allergy to soy, purified isoflavones, peanuts, fish, and/or genistein.
• Hepatitis screen (serology) positive or not performed
• Drug screen positive or not performed (at least amphetamines, benzodiazepines, cannabinoides, opiates).
• Subjects on a weight reduction program or a medically supervised diet
• Unexplained weight loss or weight gain of more than 5 kg in the three months prior to the study
• History of liver or pancreas diseases
• Cardiovascular diseases, even AV-block I0 (PQ time > 220 ms) and QTc time > 450 ms
• History of breast cancer, endometrial cancer and other malignancy except basal and squamous cell skin cancer
• History of thromboembolism or deep venous thrombosis
• Any fractures within one year except for fingers, toes and facial bones
• Subjects with susceptibility for fractures as a history of being a faller
• Endometrial thickness > 6 mm
• Endometrial polyps
• Untreated hypo- or hyperthyroidism
• Insulin-dependent diabetes mellitus, Crohn's Disease, Cushing Disease etc.
• Any condition which might interfere with absorption of the investigational product (e.g. malabsorption syndrome)
• Co-medication: Anticoagulants, parathyroid hormones, corticosteroids, thiazide diuretic
• Subjects who, during the previous 24 months, received a total fee payment greater than 5'000 USD for participation in biomedical research